Compare DOV & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOV | BIIB |
|---|---|---|
| Founded | 1947 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | DOV | BIIB |
|---|---|---|
| Price | $196.08 | $170.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $213.18 | $177.40 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 01-29-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 45.52 | N/A |
| EPS | ★ 16.27 | 10.97 |
| Revenue | $7,923,358,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $5.23 | $3.61 |
| Revenue Next Year | $5.52 | N/A |
| P/E Ratio | ★ $12.24 | $15.86 |
| Revenue Growth | 2.62 | ★ 4.77 |
| 52 Week Low | $143.04 | $110.04 |
| 52 Week High | $222.31 | $185.17 |
| Indicator | DOV | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 48.03 |
| Support Level | $189.45 | $169.24 |
| Resistance Level | $203.69 | $175.94 |
| Average True Range (ATR) | 3.60 | 4.92 |
| MACD | 0.81 | -1.89 |
| Stochastic Oscillator | 64.94 | 5.98 |
Founded in 1955 by George Ohrstrom, Dover has become an industrial behemoth through the acquisition of dozens of esteemed brands. The company is organized into five segments through which it designs and manufactures highly engineered components, such as vehicle repair, factory automation, welding, aerospace, fuel dispensing, printing, liquid handling, refrigeration, and can-making equipment. It has operations around the globe but generates over half of its revenue in the United States.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).